Casdin Capital as of Dec. 31, 2017
Portfolio Holdings for Casdin Capital
Casdin Capital holds 26 positions in its portfolio as reported in the December 2017 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Sage Therapeutics (SAGE) | 10.0 | $41M | 250k | 164.71 | |
Foundation Medicine | 8.6 | $36M | 520k | 68.20 | |
Loxo Oncology | 7.4 | $30M | 360k | 84.18 | |
Blueprint Medicines (BPMC) | 6.4 | $26M | 348k | 75.41 | |
Bluebird Bio (BLUE) | 6.3 | $26M | 145k | 178.10 | |
Alnylam Pharmaceuticals (ALNY) | 6.2 | $25M | 200k | 127.05 | |
Myokardia | 5.7 | $24M | 560k | 42.10 | |
Sangamo Biosciences (SGMO) | 5.6 | $23M | 1.4M | 16.40 | |
Global Blood Therapeutics In | 4.9 | $20M | 515k | 39.35 | |
Voyager Therapeutics (VYGR) | 4.6 | $19M | 1.1M | 16.60 | |
Agios Pharmaceuticals (AGIO) | 4.5 | $18M | 320k | 57.16 | |
Fate Therapeutics (FATE) | 3.9 | $16M | 2.6M | 6.11 | |
Spark Therapeutics | 3.8 | $16M | 303k | 51.42 | |
Codexis (CDXS) | 3.2 | $13M | 1.6M | 8.35 | |
Evolent Health (EVH) | 3.2 | $13M | 1.1M | 12.30 | |
Audentes Therapeutics | 3.0 | $13M | 400k | 31.25 | |
GenMark Diagnostics | 2.8 | $11M | 2.7M | 4.17 | |
Illumina (ILMN) | 2.3 | $9.6M | 44k | 218.50 | |
Clovis Oncology | 2.1 | $8.7M | 128k | 68.00 | |
Jounce Therapeutics | 1.5 | $6.1M | 475k | 12.75 | |
Editas Medicine (EDIT) | 1.0 | $4.1M | 133k | 30.73 | |
Cytomx Therapeutics (CTMX) | 0.9 | $3.7M | 178k | 21.11 | |
Syros Pharmaceuticals | 0.7 | $2.7M | 274k | 9.73 | |
Gilead Sciences (GILD) | 0.5 | $2.1M | 30k | 71.63 | |
Beigene | 0.4 | $1.8M | 18k | 97.72 | |
Ovid Therapeutics (OVID) | 0.4 | $1.6M | 160k | 9.87 |